Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukem
Brief Summary:
The goal of this clinical research study is to learn if combining Spyrcel (dasatinib) and Dacogen (decitabine) can help to control CML. The dose level of decitabine will also be studied.
Dasatinib is designed to block the protein that is responsible for chronic myeloid leukemia.
Decitabine is designed to affect the mechanism that cells use to control the expression of certain genes, some of which are important in the progression of CML.